Boomers Should Not ...
Health Care: Drugs
Idexx Laboratories (IDXX: NASDAQ)
$83.37 -2.19 | -2.56%
05/22/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | 178.29M | 161.75M | 141.32M | 122.24M |
| Operating Gains/Losses | -3.27M | 615.00K | -1.40M | 474.00K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 3.49M | -24.81M | -6.91M | -1.16M |
| (Increase) Decrease in Inventories | -13.75M | -6.31M | -19.47M | 6.22M |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -1.30M | 13.88M | 3.48M | -9.16M |
| (Decrease) Increase In Other Current Liabilities | 3.01M | 17.56M | 30.60M | 705.00K |
| (Increase) Decrease In Other Working Capital | 10.82M | 6.00M | -10.84M | -6.92M |
| Other Non-Cash Items | 2.57M | -2.20M | -3.00M | 9.50M |
| Net Cash From Continuing Operations | 230.28M | 220.70M | 178.83M | 174.95M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 230.28M | 220.70M | 178.83M | 174.95M |
| Sale of Property, Plant & Equipment | 45.00K | 225.00K | 112.00K | 2.08M |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -66.39M | -53.46M | -39.30M | -59.08M |
| Acquisitions | 342.00K | -43.76M | 0.00 | 3.38M |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | -4.00M | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -66.00M | -97.00M | -43.19M | -53.62M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 24.17M | 28.80M | 28.86M | 16.37M |
| Repayment of Long-Term Debt | -917.00K | -863.00K | -813.00K | -33.76M |
| Repurchase of Capital Stock | -132.27M | -255.50M | -143.09M | -83.10M |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | -16.32M | 129.91M | 28.27M | 5.19M |
| Net Cash From Financing Activities | -125.34M | -97.66M | -86.77M | -95.30M |
| Effect of Exchange Rate Changes | 1.16M | 933.00K | 1.31M | 1.82M |
| Net Change in Cash & Cash Equivalents | 40.09M | 26.98M | 50.19M | 27.86M |
Portfolios with IDXX
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ProRuane Cunniff
- ContributorPharmaceutical Short Squeez...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Season Short Squee...
- Contributor6 Health Care Stocks to Gai...
- Contributor10 Funds' Best Stocks to Be...
- ProChuck Royce - Royce & Assoc...
- ContributorUptrending Issue Short-Sque...
- UserMR's Retirement
Latest IDXX Headlines from TheStreet
- Under-the-Radar Hot Industries For Small Business Profits 09.10.12 | 06:09 am
- Buy the 5 Pharma Stocks Everyone Hates 08.07.12 | 11:08 am
- IDEXX Laboratories' CEO Discusses Q2 2012 Results - Earnings Call Transcript 07.20.12 | 03:07 pm
- Idexx Stock Hits New 52-Week High (IDXX) 06.18.12 | 12:06 pm
- IDEXX Laboratories' CEO Hosts Annual Shareholder Meeting Conference (Transcript) 05.09.12 | 03:05 pm
- Idexx Reaches New 52-Week High (IDXX) 05.01.12 | 11:05 am
- IDEXX Laboratories' CEO Discusses Q1 2012 Results - Earnings Call Transcript 04.20.12 | 03:04 pm
- Idexx Reaches New 52-Week High (IDXX) 02.15.12 | 11:02 am
- IDEXX Laboratories' CEO Discusses Q4 2011 Results - Earnings Call Transcript 01.27.12 | 11:01 am
- Spending On Pets Still Strong, Says Heska CEO
01.20.12 | 08:01 am
Press Releases for IDXX
- IDEXX Laboratories Announces Increase In Share Repurchase Program And Refinancing Of Revolving Credit Facility - PR Newswire 05.13.13 | 04:05 pm
- IDEXX Laboratories To Release 2013 First Quarter Financial Results - PR Newswire 04.08.13 | 04:04 pm
- IDEXX Laboratories Names Jeffrey Fiarman Executive Vice President And General Counsel - PR Newswire 04.04.13 | 04:04 pm
- IDEXX Laboratories Announces Federal Trade Commission Final Approval Of Consent Agreement - PR Newswire 02.12.13 | 11:02 am
- IDEXX Laboratories Announces CFO Merilee Raines To Retire In May 2013 - PR Newswire 01.16.13 | 04:01 pm
- IDEXX Laboratories To Release 2012 Fourth Quarter And Full-Year Financial Results - PR Newswire 01.14.13 | 04:01 pm
- IDEXX Laboratories To Present At J.P. Morgan Healthcare Conference - PR Newswire 01.02.13 | 02:01 pm
- IDEXX Laboratories Announces Federal Trade Commission Preliminary Approval Of Consent Agreement - PR Newswire 12.21.12 | 05:12 pm
- IDEXX Laboratories To Present At Piper Jaffray 24th Annual Healthcare Conference - PR Newswire 11.16.12 | 03:11 pm
- IDEXX Laboratories To Release 2012 Third Quarter Financial Results - PR Newswire 10.10.12 | 01:10 pm
Partner Headlines for IDXX
- Abaxis Expands Vet Product Line - Analyst Blog - NASDAQ 09.21.12 | 02:09 pm
- Abaxis Expands Vet Product Line - Analyst Blog - Zacks 09.21.12 | 10:09 am
- MWI Vet Remains Neutral - Analyst Blog - NASDAQ 09.12.12 | 07:09 pm
- MWI Vet-IDEXX Bond 'Non-Exclusive' - Analyst Blog - Zacks 08.10.12 | 04:08 pm
- Idexx Laboratories Earnings Call NUGGETS: End Markets Slowdown Throughout Q2, Europe Update - Wall St. Cheat Sheet 07.23.12 | 09:07 am
- UPDATE: Feltl Reiterates IDEXX Laboratories Hold, Increases PT to $90 - Benzinga 04.23.12 | 01:04 pm
- Little Known Dividend Stock That Could Double In 2012 - Seeking Alpha 03.02.12 | 08:03 am
- Bank of America Raises PO on IDEXX Laboratories to $91 - Benzinga 01.27.12 | 09:01 am
- Top Small-Cap Value Stocks By Chuck Royce - Seeking Alpha 12.15.11 | 07:12 am
- Abaxis Remains Neutral - Analyst Blog - Zacks 03.16.11 | 09:03 pm
